Company intelligence / Profile preview

82VS

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

82VS serves as a biotech venture studio that leverages Alloy Therapeutics’ biologics and platform technologies to rapidly form asset-centric drug discovery companies, mostly in preclinical or early-stage development, with portfolio companies pursuing innovative programs in oncology, genetic diseases, autoimmune diseases, and related areas. Two companies, Broadwing Bio and Aakha Biologics, are noted as attracting significant investor interest for later-stage advancements

Therapeutic areas: ImmunologyOphthalmologyEndocrinologyNeurologyOncology
Modalities: AntibodyBispecific monoclonal antibodyTCR-mimic antibodyGenetic medicine
Industry: Investors

Partnerships

Alloy Therapeutics

Beyond the preview

Go deeper on 82VS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 82VS.

Explore the full profile